Parkinson's Disease: Symptoms, Diagnosis and Treatment

Parkinson's Disease: Symptoms, Diagnosis and Treatment

Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder — the second most common after Alzheimer's disease — affecting approximately 8–10 million people worldwide. It results from the gradual death of dopamine-producing neurons in a region of the midbrain called the substantia nigra, which is part of the basal ganglia, the brain's motor control system.

Parkinson's disease typically begins between the ages of 50 and 79 and advances slowly over years to decades. Although there is currently no cure, treatment can substantially control symptoms and maintain quality of life for many years.

How Parkinson's Disease Develops

The basal ganglia regulate the initiation, execution, and smoothness of voluntary movement. Dopamine helps regulate signalling within these movement-control circuits. In Parkinson's disease, dopamine neurons in the substantia nigra progressively degenerate. As dopamine levels fall — by the time motor symptoms appear, approximately 60–80% of these neurons have already been lost — the basal ganglia lose their ability to coordinate smooth, controlled movement.

At the cellular level, a key pathological feature is the accumulation of misfolded alpha-synuclein protein into clumps called Lewy bodies within neurons. These aggregates spread through the nervous system, causing dysfunction and neuronal death. Researchers are studying gut/body-first and brain-first pathways in Parkinson's disease. A gut or olfactory origin may apply to some disease patterns, but it is not established as the starting point for every patient.

Symptoms

Parkinson's disease produces both motor (movement-related) and non-motor symptoms.

The Four Cardinal Motor Features

1. Resting tremor — the most recognisable symptom. A rhythmic, "pill-rolling" tremor of the hand or fingers at 4–6 Hz, present at rest and suppressed by voluntary movement. Begins unilaterally; may spread to the other side. Also affects the jaw and legs.
2. Rigidity — increased resistance to passive movement throughout the range of motion ("cogwheel" rigidity when tremor is superimposed). Causes stiffness, aching muscles, and reduced arm swing when walking. Contributes to the characteristic stooped posture.
3. Bradykinesia — slowness of movement, with progressive loss of amplitude and speed (hypokinesia). Manifests as: slow shuffling gait with short steps; micrographia (progressively smaller handwriting); reduced facial expression (hypomimia — the "masked face"); difficulty with fine tasks (buttoning, typing, using utensils); soft, monotone voice (hypophonia).
4. Postural instability — difficulty maintaining upright balance; impaired righting reflexes. The main cause of falls. Typically a later feature (not required for diagnosis). Festinating gait (involuntary acceleration of steps to prevent falling) and freezing of gait (sudden inability to move the feet, as though stuck to the floor) are related phenomena.

Parkinson's disease is typically asymmetric — symptoms begin on one side and remain more pronounced on that side throughout.

Non-Motor Symptoms

Non-motor symptoms are equally important and often appear years before motor symptoms:

Autonomic dysfunction:

• Orthostatic hypotension (dizziness on standing) — often made worse by medication
• Constipation — severe and persistent; one of the earliest symptoms
• Urinary urgency and frequency
• Excessive sweating or drooling (sialorrhoea)

Neuropsychiatric:

• Depression — affects approximately 40% of patients; often precedes motor symptoms
• Anxiety — common and distressing
• Dementia — affects approximately 30% of patients, typically later in the disease; related to cortical Lewy body spread (see Lewy body dementia)
• Psychosis — visual hallucinations and delusions, often medication-related; a leading cause of hospitalisation
• Impulse control disorders — compulsive gambling, hypersexuality, binge eating; associated with dopamine agonist therapy

Sleep disorders:

• REM sleep behaviour disorder (RBD) — acting out dreams with vigorous movements during sleep; often precedes Parkinson's by years and is a strong predictor
• Insomnia and excessive daytime sleepiness
• Restless legs syndrome

Other non-motor features:

• Anosmia (loss of smell) — often the earliest symptom, years before diagnosis
• Pain — neuropathic, musculoskeletal, or akathisia-related
• Cognitive slowing and executive dysfunction (in absence of full dementia)
• Seborrhoea (greasy skin)

Diagnosis

Parkinson's disease is primarily a clinical diagnosis. The MDS criteria define motor parkinsonism as bradykinesia together with resting tremor or rigidity; the clinician then assesses supportive features, exclusions and red flags. A clear response to dopaminergic treatment supports the diagnosis but is not universally required. Postural instability alone is not an alternative qualifying motor sign. Tests may help investigate alternatives or support assessment, but no single routine blood or imaging test independently establishes the diagnosis.

Clinical Assessment

The neurologist assesses:

• Finger-tapping and hand opening/closing speed (bradykinesia)
• Tone — cogwheel rigidity on passive wrist rotation
• Resting tremor (tremor that diminishes on movement)
• Gait — reduced arm swing, shuffling, festination, freezing
• Postural stability — a clinician-performed "pull test": a backward pull at the shoulders, with the examiner ready to prevent a fall; not tapping the shoulders or a self-test

Features such as early falls, early dementia, rapid progression, symmetrical onset or poor levodopa response can prompt specialist assessment for an alternative diagnosis (atypical parkinsonism). Absence of tremor alone does not rule out Parkinson’s disease or establish atypical parkinsonism; diagnosis requires clinical assessment.

Investigations

• Brain MRI: cannot diagnose Parkinson's, but is used to exclude other causes of parkinsonism (stroke, normal pressure hydrocephalus, brain tumours). MRI may show characteristic changes in atypical parkinsonism syndromes.
• DAT scan (DaTSCAN): a SPECT imaging study that measures dopamine transporter density in the striatum. An abnormal uptake pattern may support evidence of a presynaptic dopaminergic deficit, but the scan is an adjunct to clinical assessment, not a definitive diagnosis. It cannot by itself distinguish Parkinson’s disease from multiple system atrophy or PSP. The clinician interprets the result with symptoms, examination, medicines and other possible causes.
• Levodopa trial: a dramatic, sustained response to levodopa strongly supports the diagnosis of Parkinson's disease rather than an atypical Parkinsonian syndrome.

Treatment

There is currently no disease-modifying treatment that slows neurodegeneration. Treatment is aimed at controlling symptoms.

Dopaminergic Therapy

Levodopa (combined with carbidopa or benserazide) — the most effective and best-tolerated treatment. Levodopa crosses the blood-brain barrier and is converted to dopamine. Carbidopa/benserazide prevent peripheral conversion to dopamine (reducing nausea, vomiting, and hypotension). Provides dramatic early relief of motor symptoms in >85% of patients.

Long-term complications of levodopa therapy (typically after 5–10 years):

• Motor fluctuations — "wearing off" of medication before next dose; "on-off" phenomena with unpredictable swings between good and poor control
• Dyskinesias — involuntary, writhing movements (chorea), typically at peak dose; related to pulsatile dopamine stimulation from shorter drug half-life

Dopamine agonists (pramipexole, ropinirole, rotigotine patch) — stimulate dopamine receptors directly. Levodopa generally provides greater motor benefit, while agonists may carry less early dyskinesia risk. AAN recommends levodopa as the preferred initial dopaminergic treatment for early motor symptoms; an agonist may be considered for selected younger patients after discussing trade-offs. Monitor for impulse-control disorders, sleepiness, hallucinations and other adverse effects. Delaying levodopa is not a universal treatment goal.

MAO-B inhibitors (rasagiline, selegiline) — prevent dopamine breakdown; modest symptomatic benefit; used as initial monotherapy in early disease or as adjuncts.

COMT inhibitors (entacapone, opicapone) — extend levodopa duration by inhibiting its peripheral breakdown; reduce wearing-off.

Amantadine — reduces dyskinesias; useful in later disease.

Deep Brain Stimulation (DBS)

Deep brain stimulation is the main surgical treatment for Parkinson's disease. It is appropriate when medication is no longer providing adequate control — typically with significant motor fluctuations, dyskinesias, or tremor unresponsive to medication — in patients with good cognition and no dementia.

The procedure: Under local or general anaesthesia, stereotactically guided electrodes are implanted into the subthalamic nucleus (STN) or globus pallidus internus (GPi). The electrodes are connected via subcutaneous leads to a pulse generator (IPG) implanted in the chest. Continuous high-frequency electrical stimulation modulates abnormal circuit activity.

Outcomes:

• Reduces tremor, rigidity and bradykinesia dramatically — often by 50–70%
• Reduces dyskinesias and "off" time
• Allows levodopa dose reduction, further reducing dyskinesias
• Benefit for balance and walking varies, particularly with how these symptoms respond to levodopa. Balance or speech may remain unchanged or worsen after DBS; specialist assessment and adjustment of stimulation settings are important. DBS is not a treatment for cognitive impairment.
• Stimulation settings are adjustable and the device can be turned off. That does not make the operation fully reversible: implantation and removal carry risks, and some complications can be permanent.

Physiotherapy and Occupational Therapy

• Physiotherapy targeting gait training, balance, flexibility and cardiorespiratory fitness — the LSVT BIG programme uses high-amplitude movements to counteract bradykinesia/hypokinesia
• Occupational therapy for daily living adaptations, fall prevention, handwriting aids
• LSVT LOUD speech therapy for hypophonia
• Tai chi and dance therapy with evidence for improving balance

Managing Non-Motor Symptoms

• Depression: SSRIs, SNRIs, or antidepressants not worsening parkinsonism
• Psychosis: specialist assessment may lead to quetiapine or clozapine; clozapine requires blood monitoring. Pimavanserin acts mainly through serotonin 5-HT2A inverse agonist/antagonist activity, not dopamine receptor blockade. These medicines are not risk-free: selection requires review of adverse effects and interactions, including pimavanserin’s QT-prolongation warning. The receiving clinician must confirm the local indication and availability; a US label does not establish access in China.
• Constipation: high fibre, hydration, macrogol, lubiprostone
• Orthostatic hypotension: fludrocortisone, midodrine, droxidopa
• Insomnia and RBD: melatonin, clonazepam for RBD; address sleep hygiene

Parkinson's Disease Care in China

When planning Parkinson’s disease care in China, confirm the proposed hospital’s services and clinical suitability:

• Movement disorder evaluation: confirm the specialist assessment and whether MRI or dopamine-transporter SPECT (including any proposed DaTSCAN product) is indicated and available
• DBS surgery: ask the proposed team about its experience, outcome data and available device models, including any proposed Medtronic, Abbott or Chinese-manufactured system; confirm local authorization and suitability
• Advanced DBS programming: specialist programming and adjustment services post-implantation
• Levodopa dosing optimisation and infusion options: ask whether continuous subcutaneous apomorphine or levodopa-carbidopa intestinal gel (LCIG/Duodopa) is appropriate, locally authorized and actually available at the receiving hospital
• Multidisciplinary PD rehabilitation: specialist physiotherapy, speech therapy, and neuropsychological support
• Cost: obtain the receiving hospital’s written, itemised quote and clarify separately charged coordination services before committing; this guide does not establish comparative savings.

Contact a PriumCare care navigator to arrange a Parkinson's disease assessment, DBS evaluation, or second opinion on treatment.

---

External source attribution: the original article cites MSD Manuals, authored by Hector A. Gonzalez-Usigli MD (HE UMAE Centro Médico Nacional de Occidente), and records an evidence-review year of 2025. This is the original external-source credit, not authorship or medical review of this PriumCare article.

Targeted editorial source check

• Source
• Source
• Source
• Source
• Source
• Source

Editorial source check: 25 October 2026. This update addresses the specific classification, investigation, medication or outcome claims listed in the correction record and qualifies unverified service claims. It is not a clinical review of the whole article and does not add a medical reviewer. Original publication date and existing external-source attribution are retained.

Additional targeted source clarification

Editorial source check: 25 October 2026. These changes address specific diagnostic, procedural and emergency-care statements; this is not a whole-article medical review.

• Source 1
• Source 2
• Source 3

Targeted tremor and diagnosis clarification

Editorial source check: 25 October 2026. This checks only the absence-of-tremor diagnostic statement clarified above; it is not a whole-article medical review and adds no named clinical reviewer. The original publication date is retained.

• MDS: clinical diagnostic criteria for Parkinson’s disease
• Parkinson’s UK: tremor is not present in everyone with Parkinson’s

Targeted DBS symptom-response clarification

Editorial source check: 25 October 2026. This checks only the DBS balance, speech and cognitive-symptom distinction above, not the whole article or a medical review. The original publication date is retained.

• Parkinson’s Foundation: DBS benefits, limitations and stimulation adjustments
• Parkinson’s UK: considering DBS and symptoms that do not respond to medication